Literature DB >> 22319961

Vascular invasion, perineural invasion, and tumour budding: predictors of outcome in colorectal cancer.

Johannes Betge1, Cord Langner.   

Abstract

Tumour stage reflected by the AJCC/UICC TNM system is currently regarded as the most powerful prognostic parameter in patients with colorectal cancer. However, additional histopathological markers are required to improve clinical decision-making with respect to follow-up scheduling and administration of adjuvant therapy. In this review we summarize the available literature regarding the prognostic impact of venous and lymphatic invasion, perineural invasion and tumour budding in colorectal cancer. Special emphasis was placed on patients with AJCC/UICC stage II disease, the risk of lymph node metastasis in early cancer and the prediction of local recurrence in rectal cancer. For each of the markers, the different methods of evaluation, implications resulting from different definitions used in previous studies as well as future perspectives are discussed in detail.

Entities:  

Mesh:

Year:  2011        PMID: 22319961

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  15 in total

1.  Prostate biopsy perineural invasion is not independently associated with positive surgical margins following radical retropubic prostatectomy.

Authors:  Benjamin T Ristau; Jeffrey J Tomaszewski; Yi-Fan Chen; Marnie Bertolet; Elen Woldemichael; Joel B Nelson
Journal:  World J Urol       Date:  2014-11-01       Impact factor: 4.226

2.  Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients.

Authors:  Muriel X G Draht; Kim M Smits; Benjamin Tournier; Valerie Jooste; Caroline Chapusot; Beatriz Carvalho; Arjen H G Cleven; Sarah Derks; Kim A D Wouters; Eric J T Belt; Hein B A C Stockmann; Herman Bril; Matty P Weijenberg; Piet A van den Brandt; Adriaan P de Bruïne; James G Herman; Gerrit A Meijer; Françoise Piard; Veerle Melotte; Manon van Engeland
Journal:  Mol Oncol       Date:  2014-02-02       Impact factor: 6.603

3.  Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer.

Authors:  Y F Song; Z B Xu; X J Zhu; X Tao; J L Liu; F L Gao; C L Wu; B Song; Q Lin
Journal:  Clin Transl Oncol       Date:  2016-10-14       Impact factor: 3.405

4.  Lymphovascular invasion, perineural invasion, and tumor budding are prognostic factors for stage I colon cancer recurrence.

Authors:  Seijong Kim; Jung Wook Huh; Woo Yong Lee; Seong Hyeon Yun; Hee Cheol Kim; Yong Beom Cho; Yoon Ah Park; Jung Kyong Shin
Journal:  Int J Colorectal Dis       Date:  2020-02-28       Impact factor: 2.571

Review 5.  Prognostic biomarkers in colorectal cancer: where do we stand?

Authors:  Xavier Sagaert
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

6.  Tumor size, tumor location, and antitumor inflammatory response are associated with lymph node size in colorectal cancer patients.

Authors:  Ortrun Rössler; Johannes Betge; Lars Harbaum; Karl Mrak; Jörg Tschmelitsch; Cord Langner
Journal:  Mod Pathol       Date:  2017-02-24       Impact factor: 7.842

7.  Predicting perineural invasion using histogram analysis of zoomed EPI diffusion-weighted imaging in rectal cancer.

Authors:  Lijuan Wan; Wenjing Peng; Shuangmei Zou; Qinglei Shi; Peihua Wu; Qing Zhao; Feng Ye; Xinming Zhao; Hongmei Zhang
Journal:  Abdom Radiol (NY)       Date:  2022-07-02

8.  Inclusion of cytological features in tumor grading improves prognostic stratification of patients with colorectal cancer.

Authors:  Annika Resch; Lars Harbaum; Marion J Pollheimer; Peter Kornprat; Richard A Lindtner; Cord Langner
Journal:  Int J Colorectal Dis       Date:  2016-01-26       Impact factor: 2.571

Review 9.  Prognostic stratification of colorectal cancer patients: current perspectives.

Authors:  Nora I Schneider; Cord Langner
Journal:  Cancer Manag Res       Date:  2014-07-02       Impact factor: 3.989

10.  LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.

Authors:  Yun-Ting Lou; Chao-Wen Chen; Yun-Ching Fan; Wei-Chiao Chang; Chien-Yu Lu; I-Chen Wu; Wen-Hung Hsu; Ching-Wen Huang; Jaw-Yuan Wang
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.